Share Facebook Twitter LinkedIn Pinterest Email SpringWorks stock rallies 18% post-market on FDA approval of Ogsiveo
Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix (NASDAQ:FLGT)February 27, 2026